Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carperitide - Asubio Pharma

Next Previous
X
Search
Drug Profile

Carperitide - Asubio Pharma

Alternative Names: HANP; hANP(99-126); Human atrial natriuretic peptide; SUN 4936; SUN 4936h; SUN 4936r; SUN Y4936r; SUN4936c

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asubio Pharma
  • Developer Asubio Pharma; Asubio Pharmaceuticals; Zeria
  • Class Amino acids; Heart failure therapies; Natriuretic peptides; Peptides
  • Mechanism of Action Atrial peptide agonists; Diuretics; Natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Discontinued Adult respiratory distress syndrome; Myocardial infarction

Most Recent Events

  • 25 Aug 2015 Discontinued - Phase-III for Myocardial infarction in Japan (IV)
  • 15 Jan 2008 Efficacy and adverse events data from an independent trial in acute myocardial infarction released by Asubio ,,
  • 01 Apr 2007 Daiichi Asubio Pharma is now called Asubio Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top